DXCM vs EW
Dexcom and Edwards Lifesciences, both Healthcare
Edwards Lifesciences is the larger company at $50B against $28B. On trailing earnings DXCM is the cheaper of the two at a P/E of 35.3 against 52.2, a gap that is only a bargain if the two are growing at similar rates. Over the past year DXCM returned +16% against +15% for EW. Ryufin's sector-relative Smart Score puts DXCM ahead, 8/10 against 7/10.
| Figure | DXCM | EW |
|---|---|---|
| Last close | $88.96 | $90.77 |
| Market cap | $28B | $50B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 35.3 | 52.2 |
| 1-year return | +16% | +15% |
| 5-year return | -31% | -19% |
| Ryufin Smart Scoresector-relative, 1–10 | 8/10 | 7/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Dexcom
Revenue of $1.3B in Q2 2026, net income $249M. Its largest reported line is United States, 81% of the disclosed total.
Edwards Lifesciences
Revenue of $1.7B in Q2 2026, net income $241M. Its largest reported line is Transcatheter Aortic Valve Replacement, 73% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.